Conclusion of Joint Venture and Share Transfer Agreements for Succession of Kyorin Pharmaceutical’s Generic Drug Business by Meiji Holdings Co., Ltd. and Three Other Companies

Key Points

Meiji Holdings Co., Ltd.'s subsidiary Meiji Seika Pharma, together with Daito and DBJ, will jointly invest to establish a planned company, Pharmaceutical Co-Creation Organization Inc. (provisional), and succeed Kyorin Pharmaceutical's generic drug business. This matter involves conclusion of a joint venture agreement and a share transfer agreement. The co-creation entity plans to shift to a high-volume, low-variety production model utilizing the Takaoka and Inami plants. The establishment is planned for December 2026, the preparatory absorption-type split for this preliminary transaction is scheduled for March 31, 2027, and the effective date of succession will be April 1, 2027.

Schedule and Impact Going Forward

The contract signing date for this matter is September 30, 2026, and the share transfer agreement signing date is the same day; the establishment date of the co-creation entity is planned for December 2026. After the absorption-type split resulting from this preliminary transaction, the organization and succession of the target business, including the AG business, are expected to proceed. DBJ will invest using the Supply Chain Resilience Fund and is evaluated as contributing to strengthening regional economies and industrial competitiveness.